Chinese biotech startup CellOrigin partners with Qilu Pharmaceutical to develop

Chinese biotech startup CellOrigin partners with Qilu Pharmaceutical to develop "off-the-shelf" CAR-iMAC cell therapy

Published: 05-09-2022 13:16:00 | By: Pie Kamau | hits: 3780 | Tags:

Chinese-based CellOrigin Biotech announced it has made an agreement with Qilu Pharmaceutical on strategic global collaborations to develop, manufacture and commercialize a proprietary "off-the-shelf" iPSC-derived Chimeric Antigen Receptor Macrophages (CAR-iMAC) for cancer immnotherapy.

This collaboration takes the advantages from both parties by integrating complementary technologies and expertise as well as combining industry-leading R&D, manufacture and marketing capabilities.Both parties will collaborate on new drug development and commercialization, and will push CAR-iMAC pipelines forward to clinical trials.

Tong Jiansong, CEO, CellOrigin Biotech: "We are excited to collaborate with Qilu Pharmaceutical because of its prestige in the Chinese pharmaceutical industry as well as its successful track record in new drug discovery. We (CellOrigin) will keep seeking other potential industry collaborators, jointly exploring and developing innovative anti-tumor drugs, and benefiting more cancer patients." 

Qilu Pharmaceutical said: "CellOrigin is an outstanding startup with a strong research background and valuable industry experience. It has focused on original techniques in cell therapy and gained rich expertise in GMP manufacture. It is an ideal strategic partner for novel cell therapy and it is our pleasure to collaborate with such a great biotech company."

www.qilu-pharma.com